Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized placebo-controlled double-blind study of votoplam (HTT227) in Huntington's disease
CTR20262019Phase 3Active
- Sponsor
- Novartis
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Huntington disease (HD) comparing votoplam with placebo (2 arms). Primary endpoint: Change in cUHDRS score from baseline to Month 36. Started Jul 2026; status: active.
02
Drugs
votoplam
03
Conditions
Huntington disease (HD)
Beyond the preview
Go deeper on CTR20262019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262019.